Wolfgang Miesbach: Breakthrough in Haemophilia B Treatment
Wolfgang Miesbach, Professor of Medicine at Frankfurt University Hospital, shared a proud post on LinkedIn:
”Breakthrough in Haemophilia B Treatment: First-Ever Engineered B Cell Medicine Enters Clinical Trial. Be Biopharma has reached a historic milestone by dosing the first participant in their BeCoMe-9 Phase 1/2 trial of BE-101 – the world’s first Engineered B Cell Medicine (BCM) for haemophilia B.
This revolutionary approach may represent a paradigm shift from traditional gene therapy, offering unique advantages that could transform treatment for the 40,000 people living with this bleeding disorder globally.
What Makes BE-101 Different?
Unlike AAV-based gene therapies that deliver genes directly to the liver, BE-101 uses precision CRISPR/Cas9 gene editing to engineer the patient’s own B cells ex vivo to produce Factor IX.
These modified cells then function as living “protein factories” that can potentially:
- Produce therapeutic proteins for decades (B cells naturally live 10+ years)
- Be re-dosed and titrated as needed
- Engraft without toxic preconditioning unlike other cellular therapies
Current AAV-based haemophilia B gene therapies, while successful, face several challenges:
Known AAV Limitations:
– One-time only treatment due to neutralizing antibodies
– Pre-existing immunity excludes 40-60% of patients from treatment
– Declining efficacy over time – Factor IX levels can drop significantly
– Liver toxicity requiring immunosuppression in 17-89% of patients
– Limited cargo capacity restricting therapeutic options
– Only investigated and approved for the adult population
Potential BCM Advantages:
– Re-dosable and titratable – can adjust treatment as needed
– No preconditioning required – reduces treatment burden
– Sustained production – B cells can produce proteins for decades
– Potentially broader patient eligibility – not limited by AAV immunity or the age of the patients
Challenges Ahead:
While revolutionary, BCM therapy faces its own hurdles:
- Complex manufacturing requiring sophisticated cell culture and gene editing
- Unknown long-term durability compared to 13+ year AAV data
- Potential immune responses to engineered cells
- Manufacturing scalability for broader patient access.”
Wolfgang Miesbach gives a detailed review on BeCoMe-9 ,be sure to read the full article here.
Stay updated with the latest scientific advancements in the field of hemophilia with Hemostasis Today.
-
Jun 1, 2026, 18:51Francesco Giurazza: New Publication on Glubran-2 in Acute Bleeding Patients with Coagulopathies
-
Jun 1, 2026, 18:50Donald Arnold is the Recipient of the Roberts Award – ISTH
-
Jun 1, 2026, 18:49Amirreza Jabbaripour Sarmadian: My First Paper as Corresponding Author on Upper Extremity DVT Following COVID-19 Vaccination
-
Jun 1, 2026, 18:49James P. Crowley: How Combining Vitamin D analogs with Chemotherapy Impacts Survival Outcomes
-
Jun 1, 2026, 18:42Debojyoti Chakraborty: Small But Meaningful Steps Toward A Gene Editing Trial For Sickle Cell Disease In India
-
Jun 1, 2026, 17:14Tiffany Gacel: What an Incredible Day With NBCA and The Red Bus Tour at Memorial at Gulfport?
-
Jun 1, 2026, 17:12Marie-Claire Kofi: Poster Highlights the Process of Establishing the Sickle Cell Transitions Policy Lab
-
Jun 1, 2026, 17:00Azusa Nagao: Organizing the Symposium on Women and Bleeding Disorders at JSTH Annual Meeting
-
Jun 1, 2026, 16:57Kuljeet Kaur: Approach to Anemia – More Than Just a Low Hemoglobin